$PHAT earnings report

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update. AlphAI read Phathom Pharmaceuticals's third quarter 2026 filing as solid.

third quarter 2026

AlphAI · Earnings readPHAT · third quarter 2026 · ended September 30, 2026

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

✓Solid quarter

Third-quarter net revenue increased 71% year over year and 14% sequentially, the company reported positive operating cash flow for the second consecutive quarter, GAAP net loss narrowed, and non-GAAP adjusted net income was positive. Full-year 2026 guidance was reaffirmed, although operating expenses increased and regulatory-exclusivity litigation remains unresolved.

Revenue
$84.7M
71% y/y · 14% q/q
EPS · non-GAAP
$ 0.04
FY 2026 Guidance outlook
$310–325 million
GM ~80%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenue, net, three months ended September 30, 2026GAAP$84.72M14%71%
Cost of revenue, three months ended September 30, 2026GAAP18.37M––
Gross profit, three months ended September 30, 2026GAAP66.36M––
Research and development expenses, three months ended September 30, 2026GAAP$8.7M––
Selling, general and administrative expenses, three months ended September 30, 2026GAAP$57.7M––
Total operating expenses, three months ended September 30, 2026GAAP$66.4M––
Non-GAAP operating expenses excluding stock-based compensation, three months ended September 30, 2026non-GAAP$60.5M––
Loss from operations, three months ended September 30, 2026GAAP−85K––
Interest income, three months ended September 30, 2026GAAP1.6M––
Interest expense, three months ended September 30, 2026GAAP−15.39M––
Other expense, net, three months ended September 30, 2026GAAP−25K––
Total other expense, three months ended September 30, 2026GAAP−13.81M––
Net loss and comprehensive loss, three months ended September 30, 2026GAAP−$13.90M––
Net loss per share, basic and diluted, three months ended September 30, 2026GAAP$ (0.16)––
Non-GAAP adjusted net income (loss), three months ended September 30, 2026non-GAAP$2.99M––
Non-GAAP net income (loss) per share, basic and diluted, three months ended September 30, 2026non-GAAP$ 0.04––
Weighted-average shares of common stock outstanding, basic and diluted, three months ended September 30, 2026GAAP84,892,631––
Stock-based compensation, three months ended September 30, 2026other5.92M––
Product revenue, net, nine months ended September 30, 2026GAAP$217.3M––
Cost of revenue, nine months ended September 30, 2026GAAP45.46M––
Gross profit, nine months ended September 30, 2026GAAP171.8M––
Research and development expenses, nine months ended September 30, 2026GAAP24.33M––
Selling, general and administrative expenses, nine months ended September 30, 2026GAAP167.0M––
Total operating expenses, nine months ended September 30, 2026GAAP191.4M––
Loss from operations, nine months ended September 30, 2026GAAP−19.53M––
Net loss and comprehensive loss, nine months ended September 30, 2026GAAP−$61.85M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$ (0.74)––
Non-GAAP adjusted net income (loss), nine months ended September 30, 2026non-GAAP−$11.83M––
Non-GAAP net income (loss) per share, basic and diluted, nine months ended September 30, 2026non-GAAP$ (0.14)––
Cash and cash equivalents, September 30, 2026GAAP$184.6Man increase of $2.1 million–
Total assets, September 30, 2026GAAP$345.0M––
Total liabilities, September 30, 2026GAAP$692.7M––
Total stockholders' deficit, September 30, 2026GAAP−$347.6M––
VOQUEZNA prescriptions filled, third quarter 2026otherapproximately 380,000––
Covered VOQUEZNA prescriptions, third quarter 2026otherapproximately 248,000approximately 19%–
Cash-pay VOQUEZNA prescriptions, third quarter 2026other132,000approximately 6%–
Covered prescriptions as a percentage of total quarterly prescriptions, third quarter 2026otherapproximately 65%––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

FY 2026 Guidance outlook

  • Revenue$310–325 million
  • Gross margin~80%
  • Operating expenses$235–245 million, non-GAAP operating expenses, excluding stock-based compensation
  • NoteGross-to-net discount 55–59%

What drove it

  • Net-revenue growth was attributed to continued growth from execution of Phathom's commercial strategy.
  • Approximately 380,000 total VOQUEZNA prescriptions were filled during the third quarter 2026.
  • The company cited growing VOQUEZNA prescribing depth among GI providers and initiatives intended to improve physician prescribing and patient access.
  • Operating-expense growth reflected higher clinical development costs, commercial investment supporting the sales force and Access First initiatives, promotional costs, and personnel-related expenses.
  • The company introduced a new BlinkRx copay offering at the end of the third quarter under which eligible commercially insured patients may pay as little as $0 for VOQUEZNA.

Concerns

  • Total operating expenses increased to $66.4 million from $58.6 million in the prior-year period.
  • GAAP net loss remained $13.9 million and interest expense was $15.4 million for the third quarter 2026.
  • Total liabilities were $ 692,659 (in thousands) and total stockholders' deficit was $ (347,639) (in thousands) as of September 30, 2026.
  • BDR Pharmaceuticals and a second purported ANDA filer may succeed in challenging regulatory exclusivity, according to the company's risk disclosure.
  • The FDA public comment docket regarding issues raised in the exclusivity litigation has comments due November 23, 2026.

What to watch

  • Topline results from the 12-week blinded treatment portion of the Phase 2 pHalcon-EoE-201 trial are expected during the fourth quarter 2026.
  • Topline results from the pHalcon-NERD-302 registrational Phase 3 study are expected in the first quarter 2028.
  • The FDA public comment docket closes November 23, 2026, and the company intends to defend the regulatory exclusivity reflected in the Orange Book through May 3, 2032.
  • Execution against FY 2026 net revenue guidance of $310–325 million, gross-to-net discount guidance of 55–59%, gross-margin guidance of ~80%, and non-GAAP operating-expense guidance of $235–245 million, excluding stock-based compensation.

Balance sheet and cash flow

  • Cash and cash equivalents were $184.6 million as of September 30, 2026, an increase of $2.1 million compared to the second quarter ended June 30, 2026.
  • Phathom generated positive operating cash flow for the second consecutive quarter.
  • Total liabilities were $ 692,659 (in thousands) as of September 30, 2026.
  • Phathom stated that cash on hand and anticipated future cash generated from operations will be sufficient to invest in its business and satisfy all outstanding debt obligations without requiring additional debt or equity financing.

Analysis

Phathom reported third-quarter 2026 net revenue of $84.7 million, up 71% from $49.5 million in the third quarter of 2025 and up 14% from the second quarter of 2026. The company attributed the increase to continued execution of its commercial strategy. Commercial activity included approximately 380,000 VOQUEZNA prescriptions filled during the quarter, including approximately 248,000 covered prescriptions and 132,000 cash-pay prescriptions. Covered prescription volume increased approximately 19% sequentially, while cash-pay prescription volume increased approximately 6% sequentially.

Profitability improved materially from the prior-year quarter. Gross profit was 66,355 (in thousands), compared with 43,314 (in thousands), while loss from operations narrowed to 85 (in thousands) from 15,271 (in thousands). GAAP net loss narrowed to $13.9 million from $30.0 million. On a non-GAAP basis, adjusted net income was $3.0 million, compared with a non-GAAP adjusted net loss of $11.2 million. The non-GAAP measure excludes stock-based compensation, non-cash interest on the revenue interest financing liability, and interest expense related to amortization of debt discount on the term loan.

Expense discipline improved relative to the nine-month comparison, but quarterly spending increased. Third-quarter total operating expenses were $66.4 million versus $58.6 million in the prior-year period, driven by clinical-development and regulatory costs, promotional expense, personnel costs, and commercial investment. Non-GAAP operating expenses excluding stock-based compensation were $60.5 million, versus $49.3 million. Stock-based compensation declined to $5.9 million from $9.3 million. Interest expense remained substantial at 15,387 (in thousands) for the quarter.

Liquidity increased during the quarter. Cash and cash equivalents were $184.6 million at September 30, 2026, up $2.1 million versus June 30, 2026, and the company reported positive operating cash flow for the second consecutive quarter. The balance sheet also showed total liabilities of $ 692,659 (in thousands) and total stockholders' deficit of $ (347,639) (in thousands). Management stated that cash on hand and anticipated future cash generated from operations are expected to fund investment and satisfy outstanding debt obligations without additional debt or equity financing.

Phathom reaffirmed its FY 2026 guidance for net revenue of $310–325 million, gross-to-net discount of 55–59%, gross margin of ~80%, and non-GAAP operating expenses excluding stock-based compensation of $235–245 million. Operational catalysts include expected fourth-quarter 2026 topline results for the Phase 2 EoE trial and expected first-quarter 2028 results for the Phase 3 as-needed NERD study. The principal non-operating issue is the regulatory-exclusivity dispute: the company cites Orange Book NCE exclusivity through May 3, 2032, while litigation and an FDA public comment process remain ongoing.

Management, verbatim

We are pleased to report continued solid revenue growth and improved operating profitability for the third quarter.

Steve Basta, President and Chief Executive Officer of Phathom

We continue to grow VOQUEZNA prescribing depth among GI providers and have implemented several initiatives designed to make it easier for physicians to prescribe and patients to obtain our first-in-class GERD treatment.

Steve Basta, President and Chief Executive Officer of Phathom

Our third quarter results reflect Phathom’s significant financial transformation, with revenue growth of 71% year over year and positive cash flow from operations for the second consecutive quarter.

Sanjeev Narula, Chief Financial and Business Officer of Phathom

Not in the filing

stated, not guessed
  • Previous-release outlook was not provided, so no comparison with prior guidance is available.
  • GAAP gross margin for the third quarter 2026 was not reported.
  • A quantified operating cash flow amount was not reported.
  • Free cash flow was not reported.
  • Individual debt balances and debt maturities were not reported.
  • Capital returns, including share repurchases and dividends, were not reported.
  • A quantitative GAAP-to-non-GAAP reconciliation for FY 2026 guided operating expenses was not provided.
  • Prior-quarter values were not reported for most income-statement metrics.
  • No reportable revenue segments were disclosed.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about PHAT earnings dates

When is Phathom Pharmaceuticals's next earnings date?
AlphAI has no date for PHAT yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.